Compare GeneDx Holdings Corp (WGS) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GeneDx Holdings Corp vs Workiva Inc — how do they compare? GeneDx Holdings Corp trades at $86.53 (market cap $2.58B), while Workiva Inc trades at $72.76 (market cap $3.96B). The key difference: Workiva Inc is the larger of the two by market cap, and Workiva Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| WGS | WK | |
|---|---|---|
Market Cap | $2.58B | $3.96B |
Sector | Technology | Technology |
52-Week High | $167.51 | $93.31 |
52-Week Low | $34.51 | $44.31 |
Enterprise Value | $2.61B | $3.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
WGS trades at $85.87, down 0.14% on the day, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4 million, beating estimates, and achieved adjusted profitability ahead of schedule. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics, driving positive sentiment.
Outlook is cautiously optimistic due to strong analyst support (90.9% buy ratings) and revenue growth, but risks include negative net income margins, high valuation multiples, and ongoing class action lawsuits. The stock's upside potential hinges on sustained operational improvements and market expansion in genomics diagnostics.
Workiva (WK) trades at $73.71, down 3.71% today but showing strong fundamental momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical positioning near key support at $72 with an overall bullish signal from moving averages. Recent Q2 2026 results showed 19% revenue growth to $255 million, exceeding guidance, while the company continues to expand its AI capabilities with new product launches.
The outlook remains positive with 89% analyst buy ratings and an $82.50 consensus target offering 12% upside. However, elevated valuation multiples (P/E 86.6) and negative 2025 net income present risks. Key catalysts include continued AI adoption and Q3 earnings, while competition and execution risks warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
